New bundled payment program successful in lowering costs

The newest bundled payment program is a money-saver for CMS and Medicare, according to a recent study published in the New England Journal of Medicine. The findings are on par with previous studies that revealed other bundles are achieving their goals of lowering healthcare costs and improving care outcomes.

The Bundled Payments for Care Improvement Initiative (BPCI), which ties reimbursement payments to an episode of care and patient outcomes, has four broadly defined models where organizations enter into financial and performance accountability payment arrangements for episodes of care––the procedure plus 90 days of care and follow-up after discharge. Medicare implemented a new mandatory bundled payment program in 2016, the Comprehensive Care for Joint Replacement (CJR) for hip and knee replacements.

“Like other bundled-payment programs, CJR was designed to provide financial incentives for hospitals to reduce spending without compromising quality across an entire episode of care during the index hospitalization and after discharge,” Michael Barnett, MD, study author and assistant professor of health policy and management at Harvard T.H. Chan School of Public Health, et al. wrote.

Using Medicare claims from 2015 to 2017––the first two years of bundled payments in the CJR program and a period prior to implementation––researchers analyzed outcomes, rates of postsurgical complications and the percentage of high-risk patients. Researchers looked at procedures in 75 metropolitan statistical areas with the mandatory bundles and 121 control areas.

Over the two-year period, 280,161 hip or knee replacement procedures took place in 803 hospitals in the treatment areas, compared to 377,278 procedures in 962 hospitals in control areas.

Those in the CJR model has lower spending per joint-replacement episode in the treatment areas compared to the control areas, according to the analysis. Namely, CJR procedures cost $812, or 3.1 percent less.

“Institutional spending on hip- or knee-replacement episodes decreased from $25,903 to $23,915 in the treatment group and from $24,596 to $23,238 in the control group,” Barnett et al. wrote.

The spending decrease was mostly driven by a 5.9 percent decrease in the percentage of patients who were discharged to post-acute care facilities, such as skilled nursing facilities. The CJR program also did not have much of an impact on the rate of complications or the percentage of high-risk patients, underscoring quality care.

“In the first 2 years of the CJR program, there was a modest reduction in spending per hip- or knee-replacement episode, without an increase in rates of complications,” Barnett and colleagues. “This decrease in payments grew over an 18-month period, which raises the possibility that CJR could lead to greater reductions in payments as hospitals adapt to the new payment model.”

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.